Bensen Therapeutics Limited 06025726 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is is the holding of licences and associated patents for drugs being developed and undergoing clinical trials. Digita Accounts Production Advanced 6.30.9574.0 true true 06025726 2023-01-01 2023-12-31 06025726 2023-12-31 06025726 core:RetainedEarningsAccumulatedLosses 2023-12-31 06025726 core:ShareCapital 2023-12-31 06025726 core:SharePremium 2023-12-31 06025726 core:CurrentFinancialInstruments 2023-12-31 06025726 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 06025726 core:OtherResidualIntangibleAssets 2023-12-31 06025726 bus:SmallEntities 2023-01-01 2023-12-31 06025726 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 06025726 bus:FilletedAccounts 2023-01-01 2023-12-31 06025726 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 06025726 bus:RegisteredOffice 2023-01-01 2023-12-31 06025726 bus:Director1 2023-01-01 2023-12-31 06025726 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 06025726 core:IntangibleAssetsOtherThanGoodwill 2023-01-01 2023-12-31 06025726 core:OtherResidualIntangibleAssets 2023-01-01 2023-12-31 06025726 countries:UnitedKingdom 2023-01-01 2023-12-31 06025726 2022-12-31 06025726 core:OtherResidualIntangibleAssets 2022-12-31 06025726 2022-01-01 2022-12-31 06025726 2022-12-31 06025726 core:RetainedEarningsAccumulatedLosses 2022-12-31 06025726 core:ShareCapital 2022-12-31 06025726 core:SharePremium 2022-12-31 06025726 core:CurrentFinancialInstruments 2022-12-31 06025726 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 06025726 core:OtherResidualIntangibleAssets 2022-12-31 06025726 core:IntangibleAssetsOtherThanGoodwill 2022-01-01 2022-12-31 iso4217:GBP xbrli:pure

Registration number: 06025726

Bensen Therapeutics Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2023

 

Bensen Therapeutics Limited

Contents

Balance Sheet

1

Notes to the Unaudited Financial Statements

2 to 3

 

Bensen Therapeutics Limited

(Registration number: 06025726)
Balance Sheet as at 31 December 2023

Note

2023
£

2022
£

Fixed Assets

 

Intangible assets

4

253,800

1,040,000

Current assets

 

Debtors

5

1

1

Net assets

 

253,801

1,040,001

Capital and Reserves

 

Called up share capital

101

101

Share premium reserve

1,039,900

1,039,900

Retained Earnings

(786,200)

-

Shareholders' funds

 

253,801

1,040,001

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 30 August 2024
 

.........................................
A R Boyce
Director

 

Bensen Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Ruffles Barn Brookside
Dalham
Newmarket
CB8 8TG
England

These financial statements were authorised for issue by the director on 30 August 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in Sterling, which is the functional currency of the company.

Going concern

The financial statements have been prepared on a going concern basis.

Intangible assets

A revaluation model has been adopted based on the price paid for the shares in the holding company, Bensen Pharma Limited.

Trade Debtors

Trade Debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Bensen Therapeutics Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2022 - 0).

4

Intangible assets

Other intangible assets
 £

Total
£

Cost or valuation

At 1 January 2023

1,040,000

1,040,000

At 31 December 2023

1,040,000

1,040,000

Amortisation

Impairment

786,200

786,200

At 31 December 2023

786,200

786,200

Carrying amount

At 31 December 2023

253,800

253,800

At 31 December 2022

1,040,000

1,040,000

Impairment

Licence agreement
The intangible has been revalued to the price paid by a group of investors to develop the licence. The amount of impairment loss included in profit or loss is £786,200 (2022 - £Nil). The impairment loss is included in loss on financial assets.

5

Debtors

Current

2023
£

2022
£

Other debtors

1

1

 

1

1